Chronixs serum DNA assays have potential to detect early stage breasts cancer.

In this new research of 575 individuals, Chronix’s proprietary assays detected and determined DNA fingerprints in the blood that indicated the presence of prostate cancer and breast cancers with 92 percent sensitivity and 100 percent specificity, significantly outperforming the published accuracy data for current diagnostic methods. Today at the 2010 ASCO Annual Meeting in Chicago The new study outcomes were presented in an oral session. Breast cancer professional, Steven Narod, M.D., F.R.C.P.C., noted, ‘These brand-new data, although early, provide further proof that Chronix’s proprietary serum DNA assays may represent a new diagnostic and prognostic platform that may identify cancer previously and even more accurately than happens to be possible. I am very happy to be dealing with Chronix to help expand validate these promising results.’ Dr.With Tay-Sachs and Sandhoff, we’ve very little to provide families when it comes to therapeutics to greatly help their kids, says Igdoura. They are orphan illnesses where there are few medications obtainable. But we feel that is a significant part of improving standard of living and potentially extending lives. Kids who are identified as having Tay-Sachs early in existence, typically die before they reach age four or five. You can find distinct phases within the condition, so we wished to find targets we’re able to hinder, to delay the horrible end result or halt it entirely, explains Igdoura. Using mice that have been genetically changed to mimic Tay-Sachs and Sandhoff, researchers found degrees of TNFa rose through the first stages of the illnesses significantly. However when TNFa was subsequently eliminated, there was a substantial improvement in the lifespan of the mice and neurological function.